Serum Hevylite® assay in the differential diagnosis of patients with high suspicion of AL Amyloidosis

• Published in: International journal of laboratory hematology 2021-06, Vol.43 (3), p.418-425
• Main Authors: Yogev, Dean, Pick, Marjorie, Slyusarevsky, Elena, Pogrebijski, Galina, Pickin, Anna, Gatt, Moshe E.
• Format: Article
• Language: English
• Subjects: AL Amyloidosis; Amyloidosis; Differential diagnosis; Hevylite assay; Immunoglobulins; Isotypes; light chain; MGUS; Multivariate analysis
• ISSN: 1751-5521; 1751-553X
• DOI: 10.1111/ijlh.13399

Introduction AL amyloidosis (AL) is a malignant form of plasma cell dyscrasia (PCD). It is insidious, and its end‐organ damage can mimic that of common diseases. At diagnosis, routine tests for monoclonal protein are insufficient for the differential diagnosis. We hypothesized that Hevylite® (HLC) isotype patterns may help discriminate between AL and benign PCD states. Methods Serum samples of patients with a high clinical suspicion of AL were prospectively tested for IgGκ, IgGλ, IgAκ, IgAλ, IgMκ, and IgMλ concentrations and ratios using Hevylite® assays in a blinded manner. The results were correlated with the final diagnosis. Results Of the 99 samples analyzed, 46 were newly diagnosed AL, and the majority, 38 (82.6%), presented with suppression of at least one HLC isotype. Of the 53 benign PCD patients, 36 (67.9%) presented with elevation of at least one HLC isotype. By multivariate analysis, Hevylite® was the best independent test predictor of AL amyloidosis. HLC suppression had an odds ratio (OR) of 14.591, and elevation an OR of 10.149, and thus were significant variables in the diagnosis and exclusion of AL. Furthermore, patients with both HLC suppression, together with no elevation, had an OR of 316.69 to be diagnosed with AL rather than a benign PCD. Conclusions Hevylite® HLC analysis for Ig isotypes patterns offers an effective non‐invasive tool in the evaluation of patients with high suspicion of AL and may assist further explorative decisions for diagnosis.